Orgenesis (NASDAQ:ORGS)

Orgenesis (NASDAQ:ORGS)


Share Price
$ 4.50
Change
0.24 (5.63 %)
Market Cap
$72.52 m
Proactive Investors - Run By Investors For Investors

Orgenesis

Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes.

EPIC: ORGS
Market: NASDAQ:ORGS
52-week High/Low: $9.250 / $3.800
Sector: Pharma & Biotech
Market Cap: $72.52 m
Website: www.orgenesis.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Orgenesis


Orgenesis Snapshot

Columns Including ORGS

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use